Literature DB >> 20635898

MUC1 immunotherapy.

Richard E Beatson1, Joyce Taylor-Papadimitriou, Joy M Burchell.   

Abstract

The overexpression and aberrant glycosylation of MUC1 is associated with a wide variety of cancers, making it an ideal target for immunotherapeutic strategies. This review highlights the main avenues of research in this field, focusing on adenocarcinomas, from the preclinical to clinical; the problems and possible solutions associated with each approach; and speculates on the direction of MUC1 immunotherapeutic research over the next 5-10 years.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20635898     DOI： 10.2217/imt.10.17

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  53 in total

Review 1.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

2.  Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.

Authors:  Kirstine Lavrsen; Caroline B Madsen; Morten G Rasch; Anders Woetmann; Niels Ødum; Ulla Mandel; Henrik Clausen; Anders E Pedersen; Hans H Wandall
Journal:  Glycoconj J       Date:  2012-08-10       Impact factor: 2.916

Review 3.  MUC1 and MUC4: switching the emphasis from large to small.

Authors:  Huguette Albrecht; Kermit L Carraway
Journal:  Cancer Biother Radiopharm       Date:  2011-06       Impact factor: 3.099

4.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

5.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

6.  Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.

Authors:  C Sanchez; R Chan; P Bajgain; S Rambally; G Palapattu; M Mims; C M Rooney; A M Leen; M K Brenner; J F Vera
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-01-08       Impact factor: 5.554

7.  Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.

Authors:  Gregory E Holt; Eckhard R Podack; Luis E Raez
Journal:  Therapy       Date:  2011-01

Review 8.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

9.  Adaptive immune activation: glycosylation does matter.

Authors:  Margreet A Wolfert; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

10.  Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.

Authors:  Elizabeth Scheid; Pierre Major; Alain Bergeron; Olivera J Finn; Russell D Salter; Robin Eady; Bader Yassine-Diab; David Favre; Yoav Peretz; Claire Landry; Sebastien Hotte; Som D Mukherjee; Gregory A Dekaban; Corby Fink; Paula J Foster; Jeffery Gaudet; Jean Gariepy; Rafick-Pierre Sekaly; Louis Lacombe; Yves Fradet; Ronan Foley
Journal:  Cancer Immunol Res       Date:  2016-09-07       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.